In this study, the high incidence of coexisting KRAS and EGFR driver mutations and the lower than expected IDH1/2 VAF suggest that IDH1/2 mutations may be branching drivers promoting subclonal progression of lung adenocarcinomas. Here, KRAS is linked to lung adenocarcinoma.